ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells

A major drawback of tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) is that primitive CML cells are able to survive TKI-mediated BCR-ABL inhibition, leading to disease persistence in patients. Investigation of strategies aiming to inhibit alternative survival pathways in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Autophagy 2016-06, Vol.12 (6), p.936-948
Hauptverfasser:	Karvela, Maria, Baquero, Pablo, Kuntz, Elodie M., Mukhopadhyay, Arunima, Mitchell, Rebecca, Allan, Elaine K., Chan, Edmond, Kranc, Kamil R., Calabretta, Bruno, Salomoni, Paolo, Gottlieb, Eyal, Holyoake, Tessa L., Helgason, G. Vignir
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antigens, CD34 - metabolism ATG7 autophagy Autophagy - drug effects Autophagy-Related Protein 7 - metabolism Basic Research Papers Cell Differentiation - drug effects Cell Respiration - drug effects Cell Survival - drug effects chronic myeloid leukemia Citric Acid Cycle - drug effects Disease Models, Animal energy metabolism Energy Metabolism - drug effects erythroid differentiation Gene Deletion Gene Knockdown Techniques glycolysis Glycolysis - drug effects Hematopoietic Stem Cells - drug effects Hematopoietic Stem Cells - metabolism Humans K562 Cells Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Metabolic Flux Analysis Metabolome - drug effects Mice Mitochondria - drug effects Mitochondria - metabolism oxidative phosphorylation Oxidative Phosphorylation - drug effects Philadelphia Chromosome Protein Kinase Inhibitors - pharmacology reactive oxygen species Reactive Oxygen Species - metabolism Stem Cells - metabolism tyrosine kinase inhibitor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!